Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T-Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity and Cancer

November 27, 2023 – Drug Discovery – Barinthus Biotherapeutics, Vaccitech, immunotherapy

New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data 

6 November 2023 — Oxford, UK — Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its phase 2 Hepatitis B trials of VTP-300 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2023, 10-14 November in Boston, Massachusetts, US.

The company also announced today that it has changed its name to Barinthus Biotherapeutics to represent the evolution and expansion of its focus beyond vaccines. The company expects to begin trading under its new name and ticker effective as of 7 November 2023.

“The company has evolved and expanded since being spun out of the University of Oxford. Whereas we began as a vaccine company having been involved in flu vaccines and then the co-invention and early development of Vaxzevria, the AstraZeneca/Oxford COVID-19 vaccine and the development of other prophylactic vaccines,” said Bill Enright, CEO of Barinthus Biotherapeutics. “Today the company is focused on the development of novel T-cell immunotherapeutic candidates, which evolved out of that initial vaccine research. We believe that guiding the capabilities of T-cells using our proprietary platform technologies provides broader developmental opportunities with a huge potential to eventually impact patients’ lives. We are excited to continue into the next chapter of the company’s story – as Barinthus Biotherapeutics.”

The company’s new name takes inspiration from “Barinthus,” the mythological navigator who guided King Arthur of Britain by ship to the island of Avalon to be healed when he was wounded. The story of the legendary king being wounded and being guided to a place of healing where he continues to live is mirrored in our proprietary platforms and technology that are designed to guide the immune system to treat infectious diseases, autoimmunity, and cancer.

Data presentations at The Liver Meeting:

Late-Breaking Abstract Acceptance¹:

Title: Preliminary Pharmacodynamics and Safety of Repeat Dosing of Imdusiran (AB-729) Followed by VTP-300 or Placebo in Virally Suppressed, Non-Cirrhotic Subjects with Chronic Hepatitis B (CHB)

Authors: Yuen MF, Agarwal K, Roberts SK, Lo GH, Hsu CW, Chuang WL, Chen CY, Su PY, Galhenage S, Yang SS, Antoniello D, Thi E, O’Brien S, Bussey L, Medvedeva E, Eley T, Patel D, Varughese T, Espiritu C, Ganchua S, Iott C, Anderson M, Fortney T, Cloherty G, Evans T, Sims K

¹ Clinical collaboration with Arbutus Biopharma Corporation.

Regular Abstract Acceptance:

Abstract Number: 46173

Title: A Phase 2b, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity and Treatment Regimens of VTP-300 Combined with Low-Dose Nivolumab (LDN) in Chronic Hepatitis B Infection.

Presentation Type: Oral Presentation

Session: Hepatitis B: New Therapies for HBV and HDV

Presentation Time: Sunday, November 12,09:15 ET

Authors: Yuen MF, Chuang WL, Avihingsanon A, Lim S, Mukherjee D, Radka K, Bussey l, Evans T, Tait D

Data Summary: VTP-300 has previously demonstrated meaningful and durable HBsAg reductions in patients with HBV as a monotherapy and in combination with LDN in a Phase 1b/2a study.  Evaluating repeat dosing of Modified Vaccinia Ankara (MVA)-HBV and the timing of PD-1 inhibitor administration in patients with chronic Hepatitis B is an important piece to optimizing the regimen of VTP-300, which may be a critical component of a functional cure regimen.

Both presentations will be available on Barinthus Biotherapeutics’ website following their release at AASLD.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Biotherapeutics. With a broad pipeline, built around four proprietary platform technologies — ChAdOx, MVA, SNAP-TI and SNAP-CI — Barinthus Biotherapeutics is advancing a pipeline of five product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilise the SNAP-CI platform to treat patients with HPV-related cancer. Barinthus Biotherapeutics’ proven scientific expertise, diverse portfolio and focus on pipeline development uniquely positions the company to navigate towards delivering treatments for people with infectious diseases, autoimmunity and cancers that have a significant impact on their everyday lives. For more information, visit www.barinthusbio.com.